Global Public Health
We support innovation across the continuum of care to help develop the new technologies, treatments and vaccines needed to make progress against the world’s most life-threatening diseases. Recognizing we can’t do this alone, we seek to bring together public and private resources, invest in science both inside and outside of our walls and offer access to our R&D capabilities.
Click a circle below to see the conditions we are targeting.
Expanding access and uptake of existing regimens for multidrug- resistant TB (MDR-TB), developing simpliﬁed treatment regimens and novel molecular approaches; companion diagnostics.TB
Novel and simpliﬁed treatment tools, including new formulations, point-of-care diagnostics and others; innovative prevention tools and strategies, including vaccines, microbicides and other education/empowerment programs.HIV
Dengue prevention and treatment; Chagas disease; Obstetric ﬁstula repair; preterm birth prevention; maternal/newborn survival; pandemic preparedness and emerging threat technologies and platforms (e.g., Ebola, Zika, etc.).OTHERS
Johnson & Johnson, in partnership with WIPO Re:Search, is proud to make available its JumpstARter library to drug discovery researchers in order to identify and advance promising drug candidates to ﬁght neglected infectious diseases. The library includes a diverse collection of 80,000 high-quality drug-like small molecules and compound fragments created to “jump-start” drug discovery collaborations.SHARING OUR MOLECULAR LIBRARIES
Johnson & Johnson Innovation is comprised of a family of complementary teams that bring meaningful solutions and flexible approaches to support collaboration. From incubation facilities to early-stage investing – from venture funding to acquisition, our teams offer partners a full range of capabilities.
Make the Connection
We look forward to our first discussion. If you would like to discuss a collaboration,
please connect with us and we will schedule a call soon.